CAR-T therapy: an in vivo CRISPR screen points to the gene pair NR4A1 and SOCS3
A Nature in vivo double-knockout CRISPR screen points to NR4A1 and SOCS3 as a gene pair to boost CAR-T cells in tumor models.
A study published online in Nature on November 4, 2026 uses an in vivo double-knockout CRISPR screen to search for combinations of genes that can make CAR-T cells more effective. The pair that gave the best results is NR4A1 and SOCS3.1 CAR-T cells are T lymphocytes modified with a chimeric antigen receptor (CAR) that leads them to recognize tumor cells. According to the authors, this therapy has transformed the treatment of blood cancers, but its effectiveness remains limited by several negative regulation mechanisms inside T lymphocytes.1
What is a double-knockout screen?
A knockout means switching off a gene using the CRISPR editing technique. In a double knockout (DKO), two genes are switched off together, to see whether the pair works better than the single genes.1 The screen is high-throughput, meaning it tests many combinations in parallel, and it is carried out in vivo, that is, in a living organism and not only in a test tube. The authors identified several gene pairs that are both effective and synergistic, and they describe the method as a way to quickly discover combined targets.1
What changes with NR4A1 and SOCS3?
The study identifies NR4A1 and SOCS3 as the best pair. Whole-transcriptome profiling and in vivo single-cell RNA sequencing show that the double knockout specifically activates metabolic pathways in CAR-T cells. These cells prove to be metabolically fitter and have higher mitochondrial activity.1 According to the authors, the double-knockout CAR-T cells showed very potent antitumor activity and long-term tumor control in several tumor models, without compromising safety characteristics. The result also surpasses several benchmark single-gene and two-gene modifications already described in the literature on T cells and CAR-T cells.1
What are the limits of the results?
The conclusions on efficacy come from experiments on the tumor models described in the study. The authors call NR4A1 and SOCS3 a promising pair of intracellular checkpoints, that is, internal brakes within the cell, for building high-performance CAR-T cells.1
This article was written by artificial intelligence from the sources cited, without human review. Automatic newsroom by Redazia.
